4TEEN4 Pharmaceuticals
4TEEN4 Pharmaceuticals develops precision medicine in critical care, focusing on the treatment of circulatory failure and shock by targeting the key mediator cDPP3. Their mission is to restore cardiac and vascular function and reduce mortality in acute cardiovascular complications where limited effective therapies are available.
Industries
Nr. of Employees
small (1-50)
4TEEN4 Pharmaceuticals
Patents
DPP3 binder directed to and binding to specific DPP3-epitopes and its use in the prevention or treatment of diseases / acute conditions that are associated with oxidative stress
US-11530276-B2
View Details
DPP3 binder directed to and binding to specific DPP3-epitopes and its use in the prevention or treatment of diseases / acute conditions that are associated with oxidative stress
US-11530276-B2
View DetailsProducts
Clinical-stage humanized monoclonal antibody inhibitor of circulating DPP3
A humanized monoclonal antibody therapeutic designed to bind and inhibit circulating DPP3 with the intent to restore cardiovascular function, reverse organ dysfunction, and reduce mortality in acute circulatory failure. The program is in clinical development with a Phase 1b/2a trial planned to start in Q2 2025 and a planned pivotal Phase 2/3 study thereafter.
invobenitug (procizumab)
A humanized monoclonal antibody that binds and inhibits cDPP3 activity to restore control over RAAS, normalize cardiovascular function, reverse organ dysfunction, and increase survival in cardiogenic and septic shock.
cDPP3
Circulating Dipeptidyl Peptidase 3 (cDPP3) biomarker assay for predicting shock and severe organ dysfunction in critically ill patients.
Clinical-stage humanized monoclonal antibody inhibitor of circulating DPP3
A humanized monoclonal antibody therapeutic designed to bind and inhibit circulating DPP3 with the intent to restore cardiovascular function, reverse organ dysfunction, and reduce mortality in acute circulatory failure. The program is in clinical development with a Phase 1b/2a trial planned to start in Q2 2025 and a planned pivotal Phase 2/3 study thereafter.
invobenitug (procizumab)
A humanized monoclonal antibody that binds and inhibits cDPP3 activity to restore control over RAAS, normalize cardiovascular function, reverse organ dysfunction, and increase survival in cardiogenic and septic shock.
cDPP3
Circulating Dipeptidyl Peptidase 3 (cDPP3) biomarker assay for predicting shock and severe organ dysfunction in critically ill patients.
Expertise Areas
- Critical care therapeutics
- Cardiogenic shock treatment development
- Biomarker discovery and validation
- Monoclonal antibody therapeutics
Key Technologies
- Monoclonal antibody therapeutics
- Circulating biomarker assays
- Preclinical animal efficacy models
- Biomarker-driven patient stratification
News & Updates
The trial confirmed that Procizumab was well tolerated with no significant safety concerns, paving the way for further clinical development.
Funds will be used to advance clinical trials for Procizumab, a novel treatment for cardiogenic shock.
A prespecified subgroup analysis of the AdrenOSS-2 trial, highlighting the potential of biomarker-guided therapy.
A study demonstrating the predictive value of DPP3 levels in COVID-19 related shock.
Recognition for research on circulating DPP3 in circulatory failure.
Major milestone supported by new lead investor Görlich GmbH & Co. 1. Biotech KG.
The trial confirmed that Procizumab was well tolerated with no significant safety concerns, paving the way for further clinical development.
Funds will be used to advance clinical trials for Procizumab, a novel treatment for cardiogenic shock.
A prespecified subgroup analysis of the AdrenOSS-2 trial, highlighting the potential of biomarker-guided therapy.
A study demonstrating the predictive value of DPP3 levels in COVID-19 related shock.
Recognition for research on circulating DPP3 in circulatory failure.
Major milestone supported by new lead investor Görlich GmbH & Co. 1. Biotech KG.